Drug news
CHMP refuses recommendation for Winfuran for Pruritus-Toray Europe
The CHMP has refused to recommend Winfuran (nalfurafine) from Toray Europe, a kappa receptor agonist and orphan drug, for severe itching in patients with end stage renal disease. The clinical evidence did not demonstrate that the drug was more effective than placebo at relieving uremic pruritus.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.